Bajorin DF - Search Results

1

Two-drug therapy in patients with metastatic germ cell tumors.

Bajorin DF, Geller NL, Weisen SF, Bosl GJ. Bajorin DF, et al. Cancer. 1991 Jan 1;67(1):28-32. doi: 10.1002/1097-0142(19910101)67:1<28::aid-cncr2820670106>3.0.co;2-3. Cancer. 1991. PMID: 1845937 Clinical Trial.

2

Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience.

Motzer RJ, Bajorin DF, Vlamis V, Weisen S, Bosl GJ. Motzer RJ, et al. Among authors: bajorin df. Semin Oncol. 1992 Dec;19(6 Suppl 12):8-11. Semin Oncol. 1992. PMID: 1336624

3

Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors.

Bajorin DF, Herr H, Motzer RJ, Bosl GJ. Bajorin DF, et al. Semin Oncol. 1992 Apr;19(2):148-58. Semin Oncol. 1992. PMID: 1372757 Review.

4

"Poor-risk" germ cell tumors: current progress and future directions.

Motzer RJ, Bajorin DF, Bosl GJ. Motzer RJ, et al. Among authors: bajorin df. Semin Oncol. 1992 Apr;19(2):206-14. Semin Oncol. 1992. PMID: 1372761 Review. No abstract available.

5

Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.

Motzer RJ, Nanus DM, O'Moore P, Scher HI, Bajorin DF, Reuter V, Tong WP, Iversen J, Louison C, Albino AP, et al. Motzer RJ, et al. Among authors: bajorin df. Cancer Res. 1992 Oct 15;52(20):5775-9. Cancer Res. 1992. PMID: 1394202 Clinical Trial.

6

A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.

Ilson DH, Motzer RJ, Kradin RL, Vogelzang NJ, Bajorin DF, Scher HI, Nanus D, O'Moore P, Marathias K, Bosl GJ. Ilson DH, et al. Among authors: bajorin df. J Clin Oncol. 1992 Jul;10(7):1124-30. doi: 10.1200/JCO.1992.10.7.1124. J Clin Oncol. 1992. PMID: 1607918 Clinical Trial.

7

Continued refinement in the treatment of germ cell tumour patients.

Bajorin DF, Bosl GJ. Bajorin DF, et al. Eur J Cancer. 1991;27(6):677-8. doi: 10.1016/0277-5379(91)90162-7. Eur J Cancer. 1991. PMID: 1648942 No abstract available.

8

Assessment of risk in metastatic testis carcinoma: impact on treatment.

Bajorin DF, Geller NL, Bosl GJ. Bajorin DF, et al. Urol Int. 1991;46(3):298-303. doi: 10.1159/000282155. Urol Int. 1991. PMID: 1656578 Review.

9

Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies.

Motzer RJ, Rodriguez E, Reuter VE, Samaniego F, Dmitrovsky E, Bajorin DF, Pfister DG, Parsa NZ, Chaganti RS, Bosl GJ. Motzer RJ, et al. Among authors: bajorin df. J Natl Cancer Inst. 1991 Mar 6;83(5):341-6. doi: 10.1093/jnci/83.5.341. J Natl Cancer Inst. 1991. PMID: 1847433

10

A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.

Steffens TA, Bajorin DF, Chapman PB, Lovett DR, Cody-Johnson BV, Templeton MA, Heelan RT, Wong GY, Portlock CS, Oettgen HF, et al. Steffens TA, et al. Among authors: bajorin df. Cancer. 1991 Sep 15;68(6):1230-7. doi: 10.1002/1097-0142(19910915)68:6<1230::aid-cncr2820680608>3.0.co;2-q. Cancer. 1991. PMID: 1873774 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

290 results

Search Page

Filters